Complement c4a - Open Access .click

Results 41 to 50 of about 389,834 (185)

Complement C4 deficiency--a plausible risk factor for non-tuberculous mycobacteria (NTM) infection in apparently immunocompetent patients. [PDF]

PLoS ONE, 2014
BackgroundNon-tuberculous mycobacteria (NTM) are ubiquitous in the environment and they infect mainly persons with underlying pulmonary diseases but also previously healthy elderly women.
Hannele Kotilainen +9 more
doaj +1 more source

Association between copy number variation of complement component C4 and Graves' disease

Journal of Biomedical Science, 2011
Background Gene copy number of complement component C4, which varies among individuals, may determine the intrinsic strength of the classical complement pathway.
Liao Wen-Ling +7 more
doaj +1 more source

Plasma protein biomarkers of hepatocellular carcinoma in HCV-infected alcoholic patients with cirrhosis. [PDF]

PLoS ONE, 2015
Hepatocellular carcinoma (HCC) is one of the most common and lethal cancers in the world, with limited options for treatment unless timely diagnosed. Chronic hepatitis C virus (HCV) infection and persistent heavy alcohol consumption are independent risk ...
Gustavo Ferrín +11 more
doaj +1 more source

A serine protease isolated from the bristles of the Amazonic caterpillar, Premolis semirufa, is a potent complement system activator. [PDF]

PLoS ONE, 2015
The caterpillar of the moth Premolis semirufa, commonly named pararama, is found in the Brazilian Amazon region. Accidental contact with the caterpillar bristles causes an intense itching sensation, followed by symptoms of an acute inflammation, which ...
Isadora Maria Villas Boas +5 more
doaj +1 more source

Hydralazine binds covalently to complement component-C4: Different reactivity of C4A AND C4B Gene-Products [PDF]

, 1985
Long-term treatment with hydralazine is sometimes associated with deposition of immune complexes and development of systemic lupus erythematosus (SLE) as an adverse side-effect. Hydralazine inhibits the covalent binding reaction of the complement protein
Law, Sai-Kit A., Edith Sim, Sim, Edith, Sai-Kit A. Law +3 more
core +1 more source

Bothrops jararaca Snake Venom Inflammation Induced in Human Whole Blood: Role of the Complement System

Frontiers in Immunology, 2022
The clinical manifestations of envenomation by Bothrops species are complex and characterized by prominent local effects that can progress to tissue loss, physical disability, or amputation. Systemic signs can also occur, such as hemorrhage, coagulopathy,
Thyago Bispo Leonel +5 more
doaj +1 more source

Higher Complement C4 Gene Copy Number Constitutes a Shared Genetic Risk Factor for Giant Cell Arteritis and IgA Vasculitis

Arthritis &Rheumatology, EarlyView.
Objective Low copy number (CN) of complement C4 isoforms and high CN of retroviral HERV‐K elements are known risk factors for many immune‐mediated inflammatory diseases (IMIDs), often showing sex‐biased effects. Here, we assessed whether CN variation within the C4 gene contributes to giant cell arteritis (GCA) and IgA vasculitis (IgAV), two complex ...
Laura Martínez‐Gutiérrez +295 more
wiley +1 more source

Navigating adverse immunostimulation: A practical guide for clinical researchers

British Journal of Clinical Pharmacology, EarlyView.
Problem Setting As drug development moves towards more complex products, early clinical development programmes are increasingly hampered by unwanted and/or unexpected activation of the immune system (adverse immune stimulation, AIS). Solution At the Centre for Human Drug Research, we have introduced standardized procedures to make AIS manageable, while
Juliette A. van den Noort +3 more
wiley +1 more source

A fully recombinant human IgG1 Fc multimer (GL-2045) inhibits complement-mediated cytotoxicity and induces iC3b

Blood Advances, 2017
: GL-2045 is a recombinant human immunoglobulin G1 (IgG1)–based Fc multimer designed to recapitulate the anti-inflammatory activities of intravenous immunoglobulin (IVIG) on the innate and adaptive immune responses. We used functional in vitro studies to
Hua Zhou +9 more
doaj +1 more source

Adverse immunostimulation in early phase clinical trials: Key findings and recommendations based on the investigator's clinical experience

British Journal of Clinical Pharmacology, EarlyView.
Problem setting The emergence of therapeutic proteins has coincided with an increase of acute adverse immunostimulation (AIS). AIS has occured in clinical trials despite compliance with regulatory guidelines on preclinical evaluation and its incidence is anticipated to increase even further.
Juliette A. van den Noort +8 more
wiley +1 more source

complement c4
female
male

medicine
complement c4b
adult

lupus erythematosus, systemic
complement system
middle aged